Side-by-side research comparison of BPC-157 and TB-500 across our PubMed, ClinicalTrials.gov, and EuropePMC corpus. 1 head-to-head study plus 60 on BPC-157 and 12 on TB-500.
| BPC-157 | TB-500 | |
|---|---|---|
| Drug class | healing peptide, gastric pentadecapeptide | healing peptide, thymosin |
| Studies in corpus | 60 | 12 |
| Highest evidence tier | rct | review |
| Evidence tier mix | review · 5 other · 4 in vitro · 3 preclinical animal · 33 rct · 2 | review · 2 in vitro · 3 other · 4 |
| Studies with explicit sample size | 1 | 0 |
| Head-to-head studies in corpus | 1 | |
Beyond the literature: here's what third-party Certificate-of-Analysis records (Janoshik, BCC, Auxlabs) say about real BPC-157 and TB-500 batches we've tested. Aggregate, public data — cross-reference against the studies below.
We tested 4842 BPC-157 batches across 1220 manufacturers, 99.15% avg purity.
We tested 2467 TB-500 batches across 828 manufacturers, 98.97% avg purity.
We hold deeper lab coverage on BPC-157 (4842 batches tested). BPC-157 edges ahead on average measured purity (99.15% vs 98.97%) — a narrow gap; weigh it against failed-batch and underdose counts above.
Studies in our corpus that mention both BPC-157 and TB-500 — the gold-standard direct comparison evidence.
For anti-doping analysts and forensic toxicologists, this study validates a practical and ethical method for identifying new biomarkers of peptide abuse. Instead of relying on difficult-to-conduct human trials, labs can use commercially available liver frac…
Looking for vendor-level purity, endotoxin, and HPLC data on BPC-157 or TB-500? TitrateLab tracks Certificate-of-Analysis records from the major peptide labs (Janoshik, BCC, Auxlabs) alongside the research above. Cross-reference vendor batches against the studies on this page.